Cargando…

Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway

BACKGROUND: Acute myeloid leukemia (AML) is initiated and maintained by a subset of self-renewing leukemia stem cells (LSCs), which contribute to the progression, recurrence and therapeutic resistance of leukemia. However, the mechanisms underlying the maintenance of LSCs drug resistance have not be...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, Chen, Hai-xuan, Zhou, Shu-yan, Wang, Shao-xiang, Zheng, Kai, Xu, Dan-dan, Liu, Yu-ting, Wang, Xiao-yan, Wang, Xiao, Yan, Hai-zhao, Zhang, Li, Liu, Qiu-ying, Chen, Wan-qun, Wang, Yi-fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357193/
https://www.ncbi.nlm.nih.gov/pubmed/25890196
http://dx.doi.org/10.1186/s12943-015-0326-0
_version_ 1782361112274010112
author Zhang, Yi
Chen, Hai-xuan
Zhou, Shu-yan
Wang, Shao-xiang
Zheng, Kai
Xu, Dan-dan
Liu, Yu-ting
Wang, Xiao-yan
Wang, Xiao
Yan, Hai-zhao
Zhang, Li
Liu, Qiu-ying
Chen, Wan-qun
Wang, Yi-fei
author_facet Zhang, Yi
Chen, Hai-xuan
Zhou, Shu-yan
Wang, Shao-xiang
Zheng, Kai
Xu, Dan-dan
Liu, Yu-ting
Wang, Xiao-yan
Wang, Xiao
Yan, Hai-zhao
Zhang, Li
Liu, Qiu-ying
Chen, Wan-qun
Wang, Yi-fei
author_sort Zhang, Yi
collection PubMed
description BACKGROUND: Acute myeloid leukemia (AML) is initiated and maintained by a subset of self-renewing leukemia stem cells (LSCs), which contribute to the progression, recurrence and therapeutic resistance of leukemia. However, the mechanisms underlying the maintenance of LSCs drug resistance have not been fully defined. In this study, we attempted to elucidate the mechanisms of LSCs drug resistance. METHODS: We performed reverse phase protein arrays to analyze the expression of anti-apoptotic proteins in the LSC-enriched leukemia cell line KG-1a. Immuno-blotting, cell viability and clinical AML samples were evaluated to verify the micro-assay results. The characteristics and transcriptional regulation of survivin were analyzed with the relative luciferase reporter assay, mutant constructs, chromatin immuno-precipitation (ChIP), quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR), and western blotting. The levels of Sp1, c-Myc, phospho-extracellular signal-regulated kinase (p-ERK), phospho-mitogen and stress-activated protein kinase (p-MSK) were investigated in paired CD34+ and CD34- AML patient samples. RESULTS: Survivin was highly over-expressed in CD34 + CD38- KG-1a cells and paired CD34+ AML patients compared with their differentiated counterparts. Functionally, survivin contributes to the drug resistance of LSCs, and Sp1 and c-Myc concurrently regulate levels of survivin transcription. Clinically, Sp1 and c-Myc were significantly up-regulated and positively correlated with survivin in CD34+ AML patients. Moreover, Sp1 and c-Myc were further activated by the ERK/MSK mitogen-activated protein kinase (MAPK) signaling pathway, modulating survivin levels. CONCLUSION: Our findings demonstrated that ERK/MSK/Sp1/c-Myc axis functioned as a critical regulator of survivin expression in LSCs, offering a potential new therapeutic strategy for LSCs therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0326-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4357193
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43571932015-03-13 Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway Zhang, Yi Chen, Hai-xuan Zhou, Shu-yan Wang, Shao-xiang Zheng, Kai Xu, Dan-dan Liu, Yu-ting Wang, Xiao-yan Wang, Xiao Yan, Hai-zhao Zhang, Li Liu, Qiu-ying Chen, Wan-qun Wang, Yi-fei Mol Cancer Research BACKGROUND: Acute myeloid leukemia (AML) is initiated and maintained by a subset of self-renewing leukemia stem cells (LSCs), which contribute to the progression, recurrence and therapeutic resistance of leukemia. However, the mechanisms underlying the maintenance of LSCs drug resistance have not been fully defined. In this study, we attempted to elucidate the mechanisms of LSCs drug resistance. METHODS: We performed reverse phase protein arrays to analyze the expression of anti-apoptotic proteins in the LSC-enriched leukemia cell line KG-1a. Immuno-blotting, cell viability and clinical AML samples were evaluated to verify the micro-assay results. The characteristics and transcriptional regulation of survivin were analyzed with the relative luciferase reporter assay, mutant constructs, chromatin immuno-precipitation (ChIP), quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR), and western blotting. The levels of Sp1, c-Myc, phospho-extracellular signal-regulated kinase (p-ERK), phospho-mitogen and stress-activated protein kinase (p-MSK) were investigated in paired CD34+ and CD34- AML patient samples. RESULTS: Survivin was highly over-expressed in CD34 + CD38- KG-1a cells and paired CD34+ AML patients compared with their differentiated counterparts. Functionally, survivin contributes to the drug resistance of LSCs, and Sp1 and c-Myc concurrently regulate levels of survivin transcription. Clinically, Sp1 and c-Myc were significantly up-regulated and positively correlated with survivin in CD34+ AML patients. Moreover, Sp1 and c-Myc were further activated by the ERK/MSK mitogen-activated protein kinase (MAPK) signaling pathway, modulating survivin levels. CONCLUSION: Our findings demonstrated that ERK/MSK/Sp1/c-Myc axis functioned as a critical regulator of survivin expression in LSCs, offering a potential new therapeutic strategy for LSCs therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0326-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-07 /pmc/articles/PMC4357193/ /pubmed/25890196 http://dx.doi.org/10.1186/s12943-015-0326-0 Text en © Zhang et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhang, Yi
Chen, Hai-xuan
Zhou, Shu-yan
Wang, Shao-xiang
Zheng, Kai
Xu, Dan-dan
Liu, Yu-ting
Wang, Xiao-yan
Wang, Xiao
Yan, Hai-zhao
Zhang, Li
Liu, Qiu-ying
Chen, Wan-qun
Wang, Yi-fei
Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway
title Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway
title_full Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway
title_fullStr Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway
title_full_unstemmed Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway
title_short Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway
title_sort sp1 and c-myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the erk-msk mapk signaling pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357193/
https://www.ncbi.nlm.nih.gov/pubmed/25890196
http://dx.doi.org/10.1186/s12943-015-0326-0
work_keys_str_mv AT zhangyi sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT chenhaixuan sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT zhoushuyan sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT wangshaoxiang sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT zhengkai sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT xudandan sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT liuyuting sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT wangxiaoyan sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT wangxiao sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT yanhaizhao sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT zhangli sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT liuqiuying sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT chenwanqun sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway
AT wangyifei sp1andcmycmodulatedrugresistanceofleukemiastemcellsbyregulatingsurvivinexpressionthroughtheerkmskmapksignalingpathway